ANDROMEDA is an important meta-analysis that aims to evaluate the long-term performance of drug-coated balloons (DCB) compared to drug-eluting stents (DES) for native vessel disease. The study, known as an investigator-initiated patient-level meta-analysis, includes about 1500 patients from four randomized clinical trials: BASKET-SMALL 2, PICCOLETO II, BELLO, and RESTORE SVD China. Preliminary results show that DCB were non-inferior to DES and were associated with fewer late adverse clinical events. This meta-analysis highlights the potential of DCB as a viable treatment option for native vessel disease.
Preliminary results of this meta-analysis were presented as a late breaking clinical trial during the CRT congress in Washington, USA, in March 2024.
The final results will be submitted to the TCT Congress 2024, Washington, USA.